Paris +

Hortense Fouilland's practice focuses on venture capital, private equity, M&A, and capital markets. She assists high-growth companies, both listed and unlisted, their managers, and private equity and industrial investors in all operations and at every stage of development, from entrepreneurial start-ups to global corporations. She also has experience in mid-cap and large-cap leveraged buyout (LBO) transactions.


  • ManoMano completes $355 million Series F financing roundJones Day represented ManoMano, an online marketplace specializing in the sale of DIY, home improvement, and gardening products, in connection with its $355 million Series F round of financing led by Dragoneer Investment Group with the participation of existing investors Temasek, General Atlantic, Eurazeo, Bpifrance, Aglaé Ventures, Kismet Holdings, and Armat Group.
  • Elaia Partners leads €4 million financing round of Mablink BioscienceJones Day represented Elaia Partners in connection with the €4 million seed round of financing of Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ platform.
  • Unseenlabs raises €20 million in Series B funding roundJones Day advised Unseenlabs, a European leader in satellite radio frequency (RF) geolocation of ships at seas, in connection with its €20 million Series B round of financing.
  • HealthHero acquires QareJones Day advised HealthHero in its acquisition of Qare, a French platform that provides medical video consultation services, backed by Kamet Ventures.
  • Nanobiotix completes $113.3 million IPO on NasdaqJones Day represented Nanobiotix S.A., a French clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, in connection with its $113.3 million initial public offering in the United States and listing on Nasdaq.
  • IntegraGen’s shareholders sell majority interest to OncoDNA in tender offerJones Day advised IntegraGen, a biotechnology company developing molecular markers for central nervous system and metabolic diseases, in connection with the public tender offer of shares by OncoDNA, a private health technology and precision medicine company focused on oncology.
  • Elaia Partners participates in €2 million financing of Honing BiosciencesJones Day represented Elaia Partners in connection with the €2 million financing of Honing Biosciences, a French bio-therapeutics company that develops and improves cell-based therapies.
  • European growth VC investor participates in €12.5 million financing round of AlmaJones Day assisted a European growth VC investor in connection with the €12.5 million financing round of Alma, a French fintech which simplified installment payments for e-commerce and in-store merchants.
  • Pharnext raises €7.7 million in private placementJones Day represented Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, in connection with its €7.7 million private placement of 1,799,061 of new Ordinary Shares.
  • Tinubu® Square acquires U.S. company eSURETY®Jones Day advised Tinubu® Square in its acquisition of U.S.-based eSURETY®, a cloud-based specialty software provider, enabling carriers, brokers, and MGAs to securely apply, quote, bond, issue, and support every form of surety as well as offering a powerful direct-to-the-consumer experience on any device from any browser, anywhere in the world.
  • Carrefour acquires Potager CityJones Day advised Carrefour Group in its acquisition of Potager City, a French distributor of online subscription-based boxes of extra-fresh and seasonal fruit and vegetables sourced via short distribution channels.
  • Valar Ventures and Alven Capital participate in €104 million Series C financing round of QontoJones Day assisted Valar Ventures and Alven Capital in connection with the €104 million Series C round of financing of Qonto, the neobank for SMEs and freelancers, which included China-based Tencent and DST Global as two new global investors.
  • Alven Capital invests in CardiologsJones Day represented Alven Capital SA in connection with its investment in Cardiologs, a company engaged in the development of an AI-based heart disease diagnostic solution by supporting physicians with unprecedented EKG data analysis and reporting capabilities.
  • Macquarie Infrastructure and Real Assets to divest stakes in Autoroutes Paris-Rhin-RhoneJones Day is advising Macquarie Infrastructure and Real Assets (Europe) Limited in the sale by subsidiaries Macquarie Infrastructure Fund 2, Macquarie Mercer Infrastructure Trust 1, and Macquarie Mercer Infrastructure Trust 2 of remaining stakes in Autoroutes Paris-Rhin-Rhone for an aggregate price of €867 million, subject to timing of completion.
  • Cyrus Capital Partners acquires, in French insolvency proceeding, of French business of Toys R UsJones Day represented Cyrus Capital Partners in connection with the acquisition, in a French insolvency proceeding, of the French business (comprised notably of 44 stores) of Toys R Us.